Protagonist Therapeutics, Inc Increase (Decrease) in Other Accounts Payable and Accrued Liabilities
Protagonist Therapeutics, Inc (PTGX) reported Increase (Decrease) in Other Accounts Payable and Accrued Liabilities of -$6.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities · last filed 2026-08-05
- Protagonist Therapeutics, Inc increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $4.19M, a 21.84% increase year-over-year.
- Protagonist Therapeutics, Inc increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$10.79M.
- Protagonist Therapeutics, Inc increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $5.41M, a 67.57% increase year-over-year.
- Protagonist Therapeutics, Inc increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $7.54M, a 42.63% increase year-over-year.
- Protagonist Therapeutics, Inc increase (decrease) in other accounts payable and accrued liabilities for fiscal 2025 was $4.58M, a 6.69% increase from fiscal 2024.
- Protagonist Therapeutics, Inc increase (decrease) in other accounts payable and accrued liabilities for fiscal 2024 was $4.29M.
- Protagonist Therapeutics, Inc increase (decrease) in other accounts payable and accrued liabilities for fiscal 2023 was -$5.60M.
- Protagonist Therapeutics, Inc increase (decrease) in other accounts payable and accrued liabilities for fiscal 2022 was -$12.71M, a 166.58% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$6.60M 10-Q · filed 2026-08-05 | -$1.19M derived: sum of 3 quarters · filed 2026-08-05 | $6.35M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$10.79M 10-Q · filed 2026-05-05 | -$5.38M derived: sum of 2 quarters · filed 2026-05-05 | $2.16M derived: sum of 3 quarters · filed 2026-05-05 | $5.60M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $5.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $12.95M derived: sum of 2 quarters · filed 2026-02-25 | $16.39M derived: sum of 3 quarters · filed 2026-08-05 | $4.58M 10-K · filed 2026-02-25 |
| 2025-09-30 | $7.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $10.98M derived: sum of 2 quarters · filed 2026-08-05 | -$833.00K 10-Q · filed 2025-11-06 | $2.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $3.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$8.38M 10-Q · filed 2026-08-05 | -$5.15M derived: sum of 3 quarters · filed 2026-08-05 | $140.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$11.82M 10-Q · filed 2026-05-05 | -$8.59M derived: sum of 2 quarters · filed 2026-05-05 | -$3.30M derived: sum of 3 quarters · filed 2026-05-05 | -$4.66M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $3.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $8.52M derived: sum of 2 quarters · filed 2026-02-25 | $7.16M derived: sum of 3 quarters · filed 2026-02-25 | $4.29M 10-K · filed 2026-02-25 |
| 2024-09-30 | $5.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.93M derived: sum of 2 quarters · filed 2025-11-06 | $1.06M 10-Q · filed 2025-11-06 | -$4.28M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$4.23M 10-Q · filed 2025-08-06 | -$9.57M derived: sum of 3 quarters · filed 2026-02-25 | -$4.17M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$2.87M 10-Q · filed 2025-05-06 | -$8.21M derived: sum of 2 quarters · filed 2026-02-25 | -$2.81M derived: sum of 3 quarters · filed 2026-02-25 | -$84.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$5.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $64.00K derived: sum of 2 quarters · filed 2026-02-25 | $2.79M derived: sum of 3 quarters · filed 2026-02-25 | -$5.60M 10-K · filed 2026-02-25 |
| 2023-09-30 | $5.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $8.12M derived: sum of 2 quarters · filed 2024-11-07 | -$259.00K 10-Q · filed 2024-11-07 | -$4.85M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | $2.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$5.66M 10-Q · filed 2024-08-06 | -$10.25M derived: sum of 3 quarters · filed 2025-02-21 | -$16.82M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | -$8.38M 10-Q · filed 2024-05-07 | -$12.97M derived: sum of 2 quarters · filed 2025-02-21 | -$19.55M derived: sum of 3 quarters · filed 2025-02-21 | -$15.99M derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | -$4.59M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -$11.16M derived: sum of 2 quarters · filed 2025-02-21 | -$7.61M derived: sum of 3 quarters · filed 2025-02-21 | -$12.71M 10-K · filed 2025-02-21 |
| 2022-09-30 | -$6.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$3.02M derived: sum of 2 quarters · filed 2023-11-02 | -$8.13M 10-Q · filed 2023-11-02 | -$3.42M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $3.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$1.55M 10-Q · filed 2023-08-03 | $3.15M derived: sum of 3 quarters · filed 2024-02-27 | $16.16M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$5.11M 10-Q · filed 2023-05-04 | -$406.00K derived: sum of 2 quarters · filed 2024-02-27 | $12.60M derived: sum of 3 quarters · filed 2024-02-27 | $14.66M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $4.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $17.71M derived: sum of 2 quarters · filed 2024-02-27 | $19.77M derived: sum of 3 quarters · filed 2024-02-27 | $19.10M 10-K · filed 2024-02-27 |
| 2021-09-30 | $13.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $15.07M derived: sum of 2 quarters · filed 2022-11-08 | $14.39M 10-Q · filed 2022-11-08 | $17.10M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $2.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.39M 10-Q · filed 2022-08-04 | $4.10M derived: sum of 3 quarters · filed 2023-03-15 | $6.84M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | -$673.00K 10-Q · filed 2022-05-05 | $2.04M derived: sum of 2 quarters · filed 2023-03-15 | $4.79M derived: sum of 3 quarters · filed 2023-03-15 | $5.87M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $2.71M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $5.46M derived: sum of 2 quarters · filed 2023-03-15 | $6.54M derived: sum of 3 quarters · filed 2023-03-15 | $5.84M 10-K · filed 2023-03-15 |
| 2020-09-30 | $2.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $3.83M derived: sum of 2 quarters · filed 2021-11-03 | $3.13M 10-Q · filed 2021-11-03 | $5.01M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $382.00K 10-Q · filed 2021-08-04 | $2.26M derived: sum of 3 quarters · filed 2022-02-28 | $1.80M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$700.00K 10-Q · filed 2021-05-04 | $1.18M derived: sum of 2 quarters · filed 2022-02-28 | $717.00K derived: sum of 3 quarters · filed 2022-02-28 | $3.45M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $1.88M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.42M derived: sum of 2 quarters · filed 2022-02-28 | $4.15M derived: sum of 3 quarters · filed 2022-02-28 | $1.10M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$462.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $2.27M derived: sum of 2 quarters · filed 2020-11-04 | -$781.00K 10-Q · filed 2020-11-04 | -$116.00K derived: sum of 4 quarters · filed 2021-03-10 |
| 2019-06-30 | $2.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$319.00K 10-Q · filed 2020-08-06 | $346.00K derived: sum of 3 quarters · filed 2021-03-10 | -$2.39M derived: sum of 4 quarters · filed 2021-03-10 |
| 2019-03-31 | -$3.05M 10-Q · filed 2020-05-07 | -$2.39M derived: sum of 2 quarters · filed 2021-03-10 | -$5.13M derived: sum of 3 quarters · filed 2021-03-10 | -$2.12M derived: sum of 4 quarters · filed 2021-03-10 |
| 2018-12-31 | $665.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | -$2.07M derived: sum of 2 quarters · filed 2021-03-10 | $937.00K derived: sum of 3 quarters · filed 2021-03-10 | $1.91M 10-K · filed 2021-03-10 |
| 2018-09-30 | -$2.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $272.00K derived: sum of 2 quarters · filed 2019-11-06 | $1.25M 10-Q · filed 2019-11-06 | $2.77M derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-06-30 | $3.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $3.98M 10-Q · filed 2019-08-07 | $5.51M derived: sum of 3 quarters · filed 2020-03-10 | $7.26M derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-03-31 | $974.00K 10-Q · filed 2019-05-08 | $2.50M derived: sum of 2 quarters · filed 2020-03-10 | $4.25M derived: sum of 3 quarters · filed 2020-03-10 | $4.41M derived: sum of 4 quarters · filed 2020-03-10 |
| 2017-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $3.28M derived: sum of 2 quarters · filed 2020-03-10 | $3.43M derived: sum of 3 quarters · filed 2020-03-10 | $4.79M 10-K · filed 2020-03-10 |
| 2017-09-30 | $1.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $1.91M derived: sum of 2 quarters · filed 2018-11-06 | $3.27M 10-Q · filed 2018-11-06 | $5.46M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-06-30 | $158.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $1.52M 10-Q · filed 2018-08-07 | $3.71M derived: sum of 3 quarters · filed 2019-03-12 | $4.71M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-03-31 | $1.36M 10-Q · filed 2018-05-09 | $3.55M derived: sum of 2 quarters · filed 2019-03-12 | $4.55M derived: sum of 3 quarters · filed 2019-03-12 | $4.14M derived: sum of 4 quarters · filed 2019-03-12 |
| 2016-12-31 | $2.19M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $3.19M derived: sum of 2 quarters · filed 2019-03-12 | $2.78M derived: sum of 3 quarters · filed 2019-03-12 | $3.40M 10-K · filed 2019-03-12 |
| 2016-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $588.00K derived: sum of 2 quarters · filed 2017-11-07 | $1.21M 10-Q · filed 2017-11-07 | $1.90M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-06-30 | -$415.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $202.00K 10-Q · filed 2017-08-08 | $896.00K derived: sum of 3 quarters · filed 2018-03-07 | $1.25M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-03-31 | $617.00K 10-Q · filed 2017-05-10 | $1.31M derived: sum of 2 quarters · filed 2018-03-07 | $1.67M derived: sum of 3 quarters · filed 2018-03-07 | |
| 2015-12-31 | $694.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $1.05M derived: sum of 2 quarters · filed 2018-03-07 | $878.00K 10-K · filed 2018-03-07 | |
| 2015-09-30 | $358.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $184.00K 10-Q · filed 2016-11-14 | ||
| 2015-06-30 | -$174.00K 10-Q · filed 2016-09-15 | |||
| 2014-12-31 | $218.00K 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |